QuantHealth Ltd.

Today, over 90% of experimental therapies that reach human trials fail to make it to market. These trials fail primarily due to lack of efficacy and safety. Some drugs shouldn't go to trial, while many that do are suboptimally designed. All this is causing trials to become increasingly longer, more expensive, and less effective while patients aren't getting the drugs they need.

With recent advances in data and AI, it has become clear that we can begin to close that gap with the help of technology. QuantHealth is taken upon itself to be a leader in the field of biosimulation, in-silico trials, and synthetic evidence generation- working with the pharmaceutical industry, academia, and regulators, hand in hand, to develop transformative AI solutions that dramatically increase the probability of success.

We envision a world where clinical trial simulations and synthetic trials are an integral part of every trial's design process and regulatory path. In this world, drugs will be developed faster and cheaper than ever before, and the burden on patients and the entire healthcare system will be dramatically reduced.